Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment
Authors
Keywords
-
Journal
Nature Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-06-05
DOI
10.1038/s41467-018-04711-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability
- (2018) Davide Amato et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Differential regulation of striatal motor behavior and related cellular responses by dopamine D2L and D2S isoforms
- (2017) Daniela Radl et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential Response to Risperidone in Schizophrenia Patients byKCNH2Genotype and Drug Metabolizer Status
- (2016) Juliane Heide et al. AMERICAN JOURNAL OF PSYCHIATRY
- Optimization of Clonazepam Therapy Adjusted to Patient’s CYP3A Status andNAT2Genotype
- (2016) Katalin Tóth et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects
- (2016) Christian R Marshall et al. NATURE GENETICS
- The genetics of drug efficacy: opportunities and challenges
- (2016) Matthew R. Nelson et al. NATURE REVIEWS GENETICS
- Presynaptic D2 Dopamine Receptors Control Long-Term Depression Expression and Memory Processes in the Temporal Hippocampus
- (2015) Jill Rocchetti et al. BIOLOGICAL PSYCHIATRY
- The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex
- (2015) Robert C. Spencer et al. BIOLOGICAL PSYCHIATRY
- Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol
- (2015) Patteet Lisbeth et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Gene Dosage in the Dysbindin Schizophrenia Susceptibility Network Differentially Affect Synaptic Function and Plasticity
- (2015) A. P. Mullin et al. JOURNAL OF NEUROSCIENCE
- Personalized medicine: Time for one-person trials
- (2015) Nicholas J. Schork NATURE
- Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders
- (2015) Joey W. Trampush et al. SCHIZOPHRENIA BULLETIN
- Brain disorders? Precisely
- (2015) T. R. Insel et al. SCIENCE
- Neural Substrates of Dopamine D2 Receptor Modulated Executive Functions in the Monkey Prefrontal Cortex
- (2014) M. Victoria Puig et al. CEREBRAL CORTEX
- Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
- (2014) Stephen M Strittmatter NATURE MEDICINE
- Schizophrenia--Time to Commit to Policy Change
- (2014) W. W. Fleischhacker et al. SCHIZOPHRENIA BULLETIN
- The Ultimate Intra-/Extra-Dimensional Attentional Set-Shifting Task for Mice
- (2013) Diego Scheggia et al. BIOLOGICAL PSYCHIATRY
- Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment
- (2013) Elsa Gilbert et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
- (2013) Berta Almoguera et al. Pharmacogenetics and Genomics
- Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study
- (2013) H. Takeuchi et al. SCHIZOPHRENIA BULLETIN
- Schizophrenia Is a Cognitive Illness
- (2013) René S. Kahn et al. JAMA Psychiatry
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
- (2012) S Miyamoto et al. MOLECULAR PSYCHIATRY
- Use-Dependent Inhibition of Synaptic Transmission by the Secretion of Intravesicularly Accumulated Antipsychotic Drugs
- (2012) Carsten H. Tischbirek et al. NEURON
- Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data
- (2012) Hitoshi Sakurai et al. SCHIZOPHRENIA BULLETIN
- Characterizing trajectories of cognitive functioning in older adults with schizophrenia: Does method matter?
- (2012) Wesley K. Thompson et al. SCHIZOPHRENIA RESEARCH
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
- (2012) Alkomiet Hasan et al. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
- Neurotensin Triggers Dopamine D2 Receptor Desensitization through a Protein Kinase C and β-Arrestin1-dependent Mechanism
- (2011) Dominic Thibault et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Developing treatments for impaired cognition in schizophrenia
- (2011) Michael J. Minzenberg et al. TRENDS IN COGNITIVE SCIENCES
- Dysbindin and Schizophrenia: It's Dopamine and Glutamate All Over Again
- (2010) Francesco Papaleo et al. BIOLOGICAL PSYCHIATRY
- Analysis of HapMap tag-SNPs in dysbindin (DTNBP1) reveals evidence of consistent association with schizophrenia
- (2010) J. Voisey et al. EUROPEAN PSYCHIATRY
- Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone
- (2010) M. Riedel et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways
- (2010) F Papaleo et al. MOLECULAR PSYCHIATRY
- Rethinking schizophrenia
- (2010) Thomas R. Insel NATURE
- The heterogeneity of antipsychotic response in the treatment of schizophrenia
- (2010) M. Case et al. PSYCHOLOGICAL MEDICINE
- Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)
- (2009) Michael Davidson et al. AMERICAN JOURNAL OF PSYCHIATRY
- Getting specialized: presynaptic and postsynaptic dopamine D2 receptors
- (2009) Claudia De Mei et al. CURRENT OPINION IN PHARMACOLOGY
- Dysbindin-1 genotype effects on emotional working memory
- (2009) C Wolf et al. MOLECULAR PSYCHIATRY
- The dysbindin-containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins and role in neurite outgrowth
- (2009) C A Ghiani et al. MOLECULAR PSYCHIATRY
- Role of dysbindin in dopamine receptor trafficking and cortical GABA function
- (2009) Y. Ji et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Schizophrenia Susceptibility Gene dysbindin Controls Synaptic Homeostasis
- (2009) D. K. Dickman et al. SCIENCE
- Executive Functioning Component Mechanisms and Schizophrenia
- (2008) John G. Kerns et al. BIOLOGICAL PSYCHIATRY
- Set-Shifting Ability and Schizophrenia: A Marker of Clinical Illness or an Intermediate Phenotype?
- (2008) Alan E. Ceaser et al. BIOLOGICAL PSYCHIATRY
- Double Dissociation of the Effects of Medial and Orbital Prefrontal Cortical Lesions on Attentional and Affective Shifts in Mice
- (2008) G. B. Bissonette et al. JOURNAL OF NEUROSCIENCE
- DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients
- (2008) Chi-Un Pae et al. NEUROSCIENCE LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now